CD44 antibody-targeted liposomal nanoparticles for molecular imaging and therapy of hepatocellular carcinoma

Biomaterials

Volumn 33, Issue 20, 2012, Pages 5107-5114

  Wang, Lina ^a   Su, Weijun ^a   Liu, Ze ^a   Zhou, Manqian ^a   Chen, Si ^a   Chen, Yanan ^a   Lu, Dan ^a   Liu, Yanhua ^a   Fan, Yan ^a   Zheng, Yizhou ^b   Han, Zhongchao ^b   Kong, Deling ^c   Wu, Joseph C ^d   Xiang, Rong ^a   Li, Zongjin ^a  

^a NANKAI UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c NANKAI UNIVERSITY   (China)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hepatocellular carcinoma; Liposomal nanoparticles; Molecular imaging; Reporter gene; Targeting

Indexed keywords

BIOLUMINESCENCE IMAGING; CANCER IMAGING; CANCER PROGRESSION; CANCER STEM CELLS; DOXORUBICIN; FIREFLY LUCIFERASE; GANCICLOVIR; GREEN FLUORESCENT PROTEIN; HEPATOCELLULAR CARCINOMA; HEPG2 CELLS; HERPES SIMPLEX VIRUS; IN-SITU; LIVER TUMORS; MOLECULAR TARGETS; NEW APPLICATIONS; RED FLUORESCENT PROTEINS; RENILLA LUCIFERASE; REPORTER GENE; REPORTER SYSTEMS; TARGETING; THERAPEUTIC STRATEGY; THYMIDINE KINASE; TUMOR THERAPY;

ANTIBODIES; BIOLUMINESCENCE; DISEASES; GENE ENCODING; MAMMALS; MOLECULAR IMAGING; NANOPARTICLES; STEM CELLS; TUMORS; VIRUSES;

GENE THERAPY;

ANTIBODY; CD44 ANTIBODY; DOXORUBICIN; FIREFLY LUCIFERASE; GANCICLOVIR; GREEN FLUORESCENT PROTEIN; LIPOSOMAL NANOPARTICLE; LIPOSOME; LUCIFERASE; NANOPARTICLE; RED FLUORESCENT PROTEIN; RENILLA LUCIFERIN 2 MONOOXYGENASE; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CANCER GENE THERAPY; CANCER STEM CELL; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG MONITORING; DRUG TARGETING; FUSION GENE; HUMAN; HUMAN CELL; LIPOSOMAL GENE DELIVERY SYSTEM; LIVER CELL CARCINOMA; MOLECULAR IMAGING; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; REPORTER GENE; TUMOR GROWTH; TUMOR MODEL;

ANIMALS; ANTIBODIES; ANTIGENS, CD44; CARCINOMA, HEPATOCELLULAR; GREEN FLUORESCENT PROTEINS; LIPOSOMES; LIVER NEOPLASMS; LUCIFERASES; MICE; MICE, INBRED NOD; MICE, SCID; MOLECULAR IMAGING; NANOPARTICLES;

ANIMALIA; MUS; RENILLA LUCIFERASE; SIMPLEXVIRUS;

EID: 84860380857     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.03.067     Document Type: Article

References (34)

1. Yang J.D., Roberts L.R. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 2010, 7:448-458.
2. Altekruse S.F., McGlynn K.A., Reichman M.E. Hepatocellular carcinoma incidence, mortality, and survival trends in the united states from 1975 to 2005. J Clin Oncol 2009, 27:1485-1491.
3. Oishi N., Wang X.Z. Novel therapeutic strategies for targeting liver cancer stem cells. Int J Biol Sci 2011, 7:517-535.
4. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
5. Haraguchi N., Ishii H., Mimori K., Tanaka F., Ohkuma M., Kim H.M., et al. CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest 2010, 120:3326-3339.
6. Czechowicz A., Kraft D., Weissman I.L., Bhattacharya D. Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches. Science 2007, 318:1296-1299.
7. + cancer stem cells in human liver cancer. Cancer Cell. 2008, 13:153-166.
8. Yang Z.F., Ngai P., Ho D.W., Yu W.C., Ng M.N., Lau C.K., et al. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology 2008, 47:919-928.
9. Jin L., Hope K.J., Zhai Q., Smadja-Joffe F., Dick J.E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006, 12:1167-1174.
10. Gadhoum Z., Leibovitch M.P., Qi J., Dumenil D., Durand L., Leibovitch S., et al. CD44: a new means to inhibit acute myeloid leukemia cell proliferation via p27Kip1. Blood 2004, 103:1059-1068.
11. Liao D., Liu Z., Wrasidlo W.J., Luo Y., Nguyen G., Chen T., et al. Targeted therapeutic remodeling of the tumor microenvironment improves an HER-2 DNA vaccine and prevents recurrence in a murine breast cancer model. Cancer Res 2011, 71:5688-5696.
12. Liao D., Liu Z., Wrasidlo W., Chen T., Luo Y., Xiang R., et al. A synthetic enzyme inhibitor is a novel targeting ligand for nanotherapeutic drug delivery inhibiting primary tumor growth without systemic toxicity. Nanomedicine 2011, 7:665-673.
13. Lo A., Lin C.T., Wu H.C. Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery. Mol Cancer Ther 2008, 7:579-589.
14. Tu Y., Kim J.S. Selective gene transfer to hepatocellular carcinoma using homing peptide-grafted cationic liposomes. J Microbiol Biotechnol 2010, 20:821-827.
15. Kim H.S., Cho H.R., Choi S.H., Woo J.S., Moon W.K. In vivo imaging of tumor transduced with bimodal lentiviral vector encoding human ferritin and green fluorescent protein on a 1.5T clinical magnetic resonance scanner. Cancer Res 2010, 70:7315-7324.
16. Shah K., Jacobs A., Breakefield X.O., Weissleder R. Molecular imaging of gene therapy for cancer. Gene Ther 2004, 11:1175-1187.
17. Akins E.J., Dubey P. Noninvasive imaging of cell-mediated therapy for treatment of cancer. J Nucl Med 2008, 49:180S-195S.
18. Wu X., Lensch M.W., Wylie-Sears J., Daley G.Q., Bischoff J. Hemogenic endothelial progenitor cells isolated from human umbilical cord blood. Stem Cells 2007, 25:2770-2776.
19. Murphy E.A., Majeti B.K., Barnes L.A., Makale M., Weis S.M., Lutu-Fuga K., et al. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci USA 2008, 105:9343-9348.
20. Cao F., Drukker M., Lin S., Sheikh A.Y., Xie X., Li Z., et al. Molecular imaging of embryonic stem cell misbehavior and suicide gene ablation. Cloning Stem Cells 2007, 9:107-117.
21. Harata M., Soda Y., Tani K., Ooi J., Takizawa T., Chen M., et al. CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells. Blood 2004, 104:1442-1449.
22. Yao X., Hu J.-F., Daniels M., Yien H., Lu H., Sharan H., et al. A novel orthotopic tumor model to study growth factors and oncogenes in hepatocarcinogenesis. Clin Cancer Res 2003, 9:2719-2726.
23. Sugahara K.N., Teesalu T., Karmali P.P., Kotamraju V.R., Agemy L., Greenwald D.R., et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 2010, 328:1031-1035.
24. Xie X., Chan K.S., Cao F., Huang M., Li Z., Lee A., et al. Imaging of STAT3 signaling pathway during mouse embryonic stem cell differentiation. Stem Cells Dev 2009, 18:205-214.
25. Tagaram H.R.S., DiVittore N.A., Barth B.M., Kaiser J.M., Avella D., Kimchi E.T., et al. Nanoliposomal ceramide prevents in vivo growth of hepatocellular carcinoma. Gut 2011, 60:695-701.
26. Chow E.K., Zhang X.-Q., Chen M., Lam R., Robinson E., Huang H., et al. Nanodiamond therapeutic delivery agents mediate enhanced chemoresistant tumor treatment. Sci Transl Med 2011, 3:73. ra21.
27. Willis M., Forssen E. Ligand-targeted liposomes. Adv Drug Deliv Rev 1998, 29:249-271.
28. Sapra P., Allen T.M. Ligand-targeted liposomal anticancer drugs. Prog Lipid Res 2003, 42:439-462.
29. Sapra P., Tyagi P., Allen T.M. Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv 2005, 2:369-381.
30. Allen T.M., Ahmad I., Lopes de Menezes D.E., Moase E.H. Immunoliposome-mediated targeting of anti-cancer drugs in vivo. Biochem Soc T 1995, 23:1073-1079.
31. Mastrobattista E., Koning G.A., Storm G. Immunoliposomes for the targeted delivery of antitumor drugs. Adv Drug Deliv Rev 1999, 40:103-127.
32. Bendas G. Immunoliposomes: a promising approach to targeting cancer therapy. BioDrugs 2001, 15:215-224.
33. Cross D., Burmester J.K. Gene therapy for cancer treatment: past, present and future. Clin Med Res 2006, 4:218-227.
34. Lentacker I., Geers B., Demeester J., De Smedt S.C., Sanders N.N. Design and evaluation of doxorubicin-containing microbubbles for ultrasound-triggered doxorubicin delivery: cytotoxicity and mechanisms involved. Mol Ther 2009, 18:101-108.